#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer

1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. 1% of patients in each group experienced treatment-related mortality. Evidence Rating Level: 1 (Excellent) Study Rundown: Limited evidence exists on combined PD-1 and HER2 blockade with chemotherapy in HER2-positive gastro-esophageal cancer. This randomized controlled trial aimed to […]

The post #VisualAbstract: Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer first appeared on 2 Minute Medicine.